re dose modulation:
Is this likely to be easily addressed through Riba dosage modulation
Flatliner,
the paper I cited discusses dose modulation of riba and interferon during therapy to manage adverse effects. dose adjustments are rather frequent, usually to address laboratory abnormalities (in the case if riba to account for the hemolytic anemia most commonly, and in the case of interferon neutropenia). discontinuation for lab abnormalities is rare however, as dose adjustments often mitigate these events. as for the current protocols, I'm not sure what specific guidelines are in place regarding dose adjustment, but I'd have to think there is lattitude for the standard adjustments in both arms, or else discontinuation rates would be unreasonably high
ps welcome to the board
Market Data 
Markets 
AI
